The effect of chitooligosaccharides on oleic acid-induced lipid accumulation in HepG2 cells  by Cao, Peiqiu et al.
Saudi Pharmaceutical Journal (2016) 24, 292–298King Saud University
Saudi Pharmaceutical Journal
www.ksu.edu.sa
www.sciencedirect.comORIGINAL ARTICLEThe eﬀect of chitooligosaccharides on oleic acid-
induced lipid accumulation in HepG2 cells* Corresponding authors. Tel./fax: +86 20 39352067.
E-mail addresses: wshxalb@163.com (J. Guo), suzhq@scnu.edu.cn
(Z. Su).
1 Peiqiu Cao and Guidong Huang contributed equally to this work
and should be regarded as joint first authors.
Peer review under responsibility of King Saud University.
Production and hosting by Elsevier
http://dx.doi.org/10.1016/j.jsps.2016.04.023
1319-0164  2016 The Authors. Production and Hosting by Elsevier B.V. on behalf of King Saud University.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Peiqiu Cao 1, Guidong Huang 1, Qingyun Yang, Jiao Guo *, Zhengquan Su *Key Research Center of Liver Regulation for Hyperlipemia SATCM/Class III Laboratory of Metabolism SATCM, Guangdong
TCM Key Laboratory for Metabolic Diseases, Guangdong Pharmaceutical University, Guangzhou 510006, China
Available online 29 April 2016KEYWORDS
Chitooligosaccharides;
Oleic acid;
Lipid accumulation;
HepG2 cellsAbstract This experiment aimed to evaluate the capacities of two types of chitooligosaccharides
(COS) with different molecular weights for the ability to eliminate lipid accumulation in hepato-
cytes. We have established a lipid accumulation model in HepG2 cells for these studies in vitro,
which was established by induction with oleic acid. The capacity of COS to eliminate lipid accumu-
lation was evaluated using three metrics: the thiazolyl blue dye absorbance (MTT value), the
morphology of intracellular lipid droplets and the triglyceride level (TG). Two types of COS with
different molecular weights (1000 Da and 3000 Da) can significantly reduce intracellular lipid
accumulation and decrease TG content in HepG2 cells, in a dose-dependent fashion. We found that
low molecular weight COS is more efficacious than high molecular weight COS. Two types of COS
can eliminate lipid accumulation induced by oleic acid in HepG2 cells, leading to an obvious
hypolipidemic effect in vitro. These results suggest that COS may be effective preventive agents
in fatty liver disease.
 2016 The Authors. Production and Hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Fatty liver diseases are divided into two categories: alcoholic
fatty liver disease (AFLD) and nonalcoholic fatty liver disease
(NAFLD) (Montilla et al., 2013). NAFLD is more common inclinical practice and can seriously impact the quality of a
patient’s life. The current clinical treatments for NAFLD
include insulin sensitization agents, lipids, diet pills, antihyper-
tensive agents, cell protective agents, anti-inflammatory
cytokine antioxidants and other types (McCullough, 2004;
Cordeiro et al., 2015). In recent years, with improvements of
the living standards and the changes of the diet structure of
the people, the incidence of NAFLD has increased year by
year, but the pathogenesis is not entirely clear. Drug treatment
is not perfect; therefore, there is an urgent need for new drugs
that can enhance prevention and treatment of NAFLD (Torres
et al., 2012).
Chitosan (CTS), a linear biopolymer comprising glu-
cosamine and N-acetyl-glucosamine residues, is an
N-deacetylated product of chitin and one of the most
abundant polysaccharides in nature (Lin et al., 2007). CTS is
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acidic solutions, and it has been widely used in the chemical
industry, environmental protection, food, pharmaceutics, med-
icine, cosmetics, agriculture and many other fields (Lin et al.,
2007; Qin et al., 2006). However, its high molecular weight
has limited its applications. Fortunately, CTS can be hydro-
lyzed enzymatically by specific chitosanases and non-specific
enzymes. The degradation products of CTS, COS, not only
can be used as drug carrier (Tan et al., 2014; Chen et al.,
2013), but also has better biological activity owing to the rise
in the water soluble (Chae et al., 2005). COS has also been
implicated in many biological activities, such as lowering
blood lipids, controlling blood pressure and blood glucose,
and producing other antidiabetic actions (Choi et al., 2012a,
2012b; Ju et al., 2010). In addition, COS has been also widely
used in the field of functional food (Je and Kim, 2012; Choi
et al., 2012a, 2012b). Increasing researchers have devoted
themselves to the study on the molecular mechanisms on the
various physiological functions of COS and related products
aforesaid, especially its anti-obesity and hypolipidemic capac-
ity (Huang et al., 2015; Zhang et al., 2011, 2012; Tao et al.,
2013). However, there has been very little research on the
use of COS for NAFLD; therefore, the goal of this study
was to simulate the pathological characteristics of clinical
NAFLD. Oleic acid-induction of HepG2 cells leads to a signif-
icant increase in lipid droplets. This system can thus be used as
a lipid accumulation model. The actions of two types of COS
with different molecular weights are evaluated for their efficacy
at reducing intracellular lipid accumulation. This study can be
used to test their potential value in the prevention and treat-
ment of fatty liver disease.
2. Materials and methods
2.1. Materials
The human hepatocellular carcinoma cell line HepG2 was pro-
vided by the Institute of Chinese Medical Science of Guang-
dong Pharmaceutical University. Drugs and reagents used in
this study include the following: Chitooligosaccharides I and
II with average molecular weights of 1000 and 3000, Shandong
Laizhou Haili Biological Products Co. Ltd., Shangdong,
China, GIBCO Dulbecco’s Modified Eagle Medium (DMEM),
Invitrogen Co. Ltd., New York, American, Fetal bovine serum
(FBS), Hyclone Co. Ltd., Utah, American, Trypsin, Amresco
Co. Ltd., Ohio, American, Sodium oleate, Tokyo chemical
industry Co. Ltd., Tokyo, Japan, Oil red O staining solution,
Zhuhai Beisuo Biological Technology Co. Ltd., Guangdong,
China, Triglyceride kits, Biosino Biotechnology & Science
Inc., Beijing, China, and Thiazolyl blue tetrazolium bromide
(MTT), Sigma Co. Ltd., San Francisco, American. All other
reagents and solvents were of analytical reagent grade.
2.2. Preparation of drug solution
Preparation of the induction solution for lipid accumulation
was performed as follows: sodium oleate was dissolved in
phosphate buffer salt (PBS) to produce a 50 mmol L1 stock
solution using a shocking water bath at 55 C, and then
dropped into PBS containing 10% FBS for a 5 mmol L1
working solution. The solution was then filtered through the0.2 lm to remove bacteria in the solution and cryopreserved
at 4 C.
Preparation of COS I solution was performed as follows:
COS I was dissolved in PBS to produce a 100 mg ml1 stock
solution, and then dropped into PBS containing 10% fetal
bovine serum to produce a 10 mg ml1 working solution.
The solution was then filtered to remove bacteria in the
solution and cryopreserved at 4 C.
Preparation of the COS II solution was performed in the
same manner as the COS I solution.
2.3. HepG2 cell culture
HepG2 cells were cultured using 13.5 g L1 DMEM culture
medium containing high glucose, 10% fetal bovine serum
and double-antibiotic solution (penicillin 100 lmolml1 and
streptomycin 100 lg ml1) in an incubator providing 5%
CO2 at 37 C. Subculture or subsequent trials were conducted
when cell confluence reached 80–90% (Nair et al., 2014).
2.4. HepG2 cell viability with the MTT method
HepG2 cells were inoculated into 96-well culture plates with
1.0  104 cells per well and cultured immediately. After 24 h
incubation in an incubator containing 5% CO2 at 37 C, the
culture medium was replaced and injected with COS I and
COS II at different concentrations. The final concentrations
were 1.0  107, 3.0  106, 1.0  106, 3.0  105, 1.0  105,
3.0  104, 1.0  104, and 3.0  103 lg L1, and were prepared
alongside the no-induction and no-COS control groups. The
final volumes of the six parallel wells in each group were
200 ll. After 24 h incubation in an incubator containing 5%
CO2 at 37 C, the experiment was conducted according to
the following steps: 20 ll of 0.5 mg mL1 MTT solution was
injected into each well of 96-well culture plates and incubated
for 4 h in the dark, culture medium was removed, 150 ll of
DMSO was injected into each well of a 96-well culture plate,
the plates were simultaneously shocked on the cell oscillator,
the absorbance was read at 485 nm (OD485), and the cell
survival rate (CSR) was calculated on the basis of OD485 to
screen the suitable concentration range of the COS I and
COS II (Mohd et al., 2014).
CSR ¼ ðAaA0Þ=ðAsA0Þ  100%:
Aa, As and A0 represent the absorbance of the experiment
group, no-COS control group and no-induction control group,
respectively, in the formula.
2.5. Oil red O staining for HepG2 cells
HepG2 cells were subcultured with 2.5  105 cells per well in
six-well culture dishes following 24 h incubation in the 37 C
incubator containing 5% CO2, and then were subsequently
divided into nine groups (with six parallel wells in each group)
as the blank control group, model group, berberine (Ber)
control group due to its prevention of lipid accumulation
in vitro and in vivo demonstrated in many studies (Zhou
et al., 2014; Hu et al., 2012), and COS I and COS II groups
with high (3.0  105 lg L1), middle (1.0  105 lg L1) and
low (3.0  104 lg L1) concentrations, respectively. The ingre-
dients in each group are shown as follows:
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containing 10% FBS.
Model group: high glucose DMEM culture medium con-
taining 10% FBS and oleic acid with a final concentration
of 0.2 mmol L1.
Ber control group: high glucose DMEM culture medium
containing 10% FBS, oleic acid and Ber with a final con-
centration of 0.2 mmol L1 and 10 lmol L1, respectively.
COS I group: high glucose DMEM culture medium con-
taining 10% FBS and oleic acid with a final concentration
of 0.2 mmol L1, COS I with final concentration of
3.0  105 (high concentration), 1.0  105 (middle concen-
tration) and 3  104 (low concentration) lg L1.
COS II group: high glucose DMEM culture medium con-
taining 10% FBS and oleic acid with a final concentration
of 0.2 mmol L1, COS II with final concentration of
3.0  105 (high concentration), 1.0  105 (middle concen-
tration), 3.0  104 (low concentration) lg L1.
After 24 h incubation, the culture medium was removed,
and the experiment was conducted according to the following
steps: 1 ml PBS was injected into each well and wells were then
rinsed three times repeatedly, 500 ll of 4% paraformaldehyde
was injected into each well for a 20 min fixation and then
cleaned with 1 ml PBS three times repeatedly, 500 ll of Oil
red O working solution was injected into each well and stained
for 15 min in room temperature, 60% isopropanol was injected
into each well for 1 min fixation and wells were cleaned with
three rinses of isopropanol to produce a white transparent
background, cell morphology and the distribution of lipid dro-
plets were observed with the inverted microscope, and
recorded as pictures, 500 ll of 60% isopropanol was injected
into each well and incubated for 15 min at room temperature,
after the extraction, 200 ll of leaching liquor was injected into
96-well culture plates, and absorbance of each well was
determined at 485 nm (Kim et al., 2013).
2.6. The determination of the intracellular TG
HepG2 cells were inoculated into 24-well culture plates at
5.0  104 cells per well and taken out after 24 h of incubation
to set up the experimental groups as the blank control group,
model group, Ber control group, and COS I and COS II
groups with three different concentrations, 3.0  105,
1.0  105, and 3.0  104 lg L1, respectively, the ingredients
in each group refer to 2.4. After 24 h incubation of the
24-well culture plates as described above, the culture solution
was removed, they were cleaned with precooled PBS for three
times and then blotted up, RIPA lysate (107 cell ml1) was
injected in each group to produce sufficient lysis, the pyrolysis
products of cells were scraped gently with cell scrapers and
transferred into 1.5 ml Eppendorf (EP) tubes, respectively,
they were shocked for 30 min and simultaneously centrifuged
for 15 min (12,000 r min1) at 4 C, supernatant was collected,
10 ll supernatant in each EP tube was used for protein
quantification by the BCA protein concentration determina-
tion kit method, the remaining supernatant was extracted by
methanol-chloroform (V/V = 2:1), allowed to stand for
30 min, centrifuged for 15 min (12,000 r min1) at 4 C, the
supernatant solution was removed and the bottom solution
dried at 70 C, 20 ll of PBS was injected for the dissolutionof lipid (Kuo et al., 2012), and intracellular concentration of
TG was determined according to the instructions of triglyc-
eride determination kits.
2.7. Statistical analysis
The experimental data are represented as average value
± standard deviation (X ± S) and analyzed by SPSS 17.0
statistical software. The significance analysis is conducted by
one-way ANOVA, with the statistical significance assigned to
P< 0.05.3. Results
3.1. Toxicological evaluation of COS I and COS II to HepG2
cells
COS I and COS II elicit some cytotoxicity at high concentra-
tions. We explored the effects of COS I and COS II in different
concentrations on normal HepG2 cell viability with the MTT
method to choose a drug concentration characterized by the
least toxicity to the cells. The results are shown in Figs. 1
and 2. The cell viability decreases gradually with an increased
concentration of COS I and COS II, suggesting that COS I and
COS II in high concentration have some toxicity to HepG2
cells. COS I and COS II have the least toxicity to HepG2 cells
at concentrations less than 3.0  105 lg L1. At this concen-
tration, the cell viability is more than 90%, indicating that
the concentration of COS I and COS II should be less than
3.0  105 lg L1 (The high, middle and low concentrations
of COS I and COS II are 3.0  105 lg L1, 1.0  105 lg L1
and 3.0  104 lg L1, respectively).3.2. HepG2 cell morphology and oil red O staining
The results of oil red O staining for HepG2 cellular morphol-
ogy by the inverted microscope are displayed in Fig. 3, and
HepG2 cells in the induced group contain a large number of
red lipid droplets fused to each other, indicating that the
HepG2 cell lipid accumulation model is established success-
fully. HepG2 red lipid droplets show a dose-dependent trend
that is characterized by decreasing number, decreasing volume
and shallow color. Compared with the induced group, the
COS I and COS II middle and low concentration groups show
obviously improved lipid accumulation and alleviated lipid
fusion in the HepG2 cells. The lipid characteristics of the mid-
dle groups are comparable to those of the Ber positive group.
The COS I and COS II high concentration groups show the
effects described above even more obviously.
3.3. The effects of COS I and COS II in different concentrations
on the HepG2 lipid accumulation model
The absorbances for HepG2 cells in each group are shown
below (Fig. 4) after the process of oil red O staining and
extraction with isopropanol. It is observed that there is a sig-
nificantly increasing lipid accumulation in HepG2 cells in the
model group compared with blank group (P< 0.001). There-
fore, the effects of COS I and COS II in the high and middle
Figure 1 Effects of COS I on proliferation of HepG2 cells.
Figure 2 Effects of COS II on proliferation of HepG2 cells.
The effect of chitooligosaccharides 295concentration groups on the reduction in lipid accumulation
are comparable to those of the Ber-positive control group.
3.4. The effects of COS I and COS II in different concentration
on the content of TG in HepG2 lipid accumulation models
We observed the effects of COS I and COS II in the high,
middle and low concentration groups (which are less toxic to
HepG2 cells) on the content of TG in the HepG2 lipid
accumulation model (Figs. 3 and 5).
There is a significantly increasing content of TG in the
model group compared with the blank control group
(P< 0.001), suggesting that the lipid accumulation model in
HepG2 cells is established successfully. Compared with
model groups, COS II in the high and middle concentrations
and COS I in the high concentrations extremely decrease the
TG content (P< 0.001). An extremely significant difference
exists between COS I at the middle concentration and
the model group (P< 0.01) and between the COS I, the
COS II and the model groups. Notably, the decrease in TG
accumulation is linearly correlated with an increasing concen-
tration of COS I and COS II in the range from 3.0  104 to
3.0  105 lg L1. Furthermore, the two COS have the
strongest suppressive effects on TG content in HepG2 cells
at 1.0  105 lg L1.4. Conclusion and discussion
NAFLD has gradually become a widespread and serious dis-
ease since the first official report of NAFLD in 1958, and
the average incidence of NAFLD is approximately 20%, with
a yearly increase. As the leading cause of hepatic dysfunction
worldwide, the typical characteristic of NAFLD is intracellu-
lar lipid accumulation in hepatocytes (Ogawa et al., 2013).
The main lipid accumulating in liver of NAFLD patients is
TG, and its accumulation results from an imbalance between
its synthesis and transformation (Sun et al., 2015; Rouabhia
et al., 2014). Genetic factors combined with the external
environment and metabolic stress result in the pathogenesis
of NAFLD, and the overwhelming theory for the molecular
mechanism of NAFLD is the ‘two-hit theory’ as shown in a
recent study (Ogawa et al., 2013; Sun et al., 2015; Rouabhia
et al., 2014). The ‘first’ hit of the ‘two-hit theory’ is the lipid
accumulation in the liver. Fatty degeneration of hepatocytes
is more susceptible to ‘second’ hit (oxidative stress, etc) than
normal one, which further promote the generation of inflam-
mation that is the development of NAFLD. Based on this the-
ory, the ‘first’ hit becomes an important target for prevention
and treatment of NAFLD. Considering from this target, the
experiment simulates lipid accumulation in hepatic cells, and
then investigates the effect of drugs on the lipid accumulation
Figure 3 Oil red O staining maps of HepG2 cells (10  40). (A) Stained control group cells, (B) Stained induced group cells, (C) Stained
10 lmol L1 berberine-positive cells, (D) Stained 3.0  105 lg L1 COS I-treated cells, (E) Stained 1.0  105 lg L1 COS I-treated
cells, (F) Stained 3.0  104 lg L1 COS I-treated cells, (G) Stained 3.0  105 lg L1 COS II-treated cells, (H) Stained 1.0  105 lg L1
COS II-treated cells, (I) Stained 3.0  104 lg L1 COS II-treated cells.
Figure 4 Effect of different experiments on lipid accumulation in HepG2 cells.
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vention and treatment of NAFLD.
HepG2 cells have been successfully used for the establish-
ment of a fatty liver cell model and because of their stable cell
characteristics such as ease of cultivation, these cells can beused to screen for preventive and therapeutic drugs and to
explore fatty liver pathogenesis (Kim et al., 2013; Kuo et al.,
2012). Long-chain fatty acids can form into lipid droplets in
cells, which lead to lipid accumulation (Montilla et al.,
2013). As the foremost component of long-chain free fatty
Figure 5 Effect of COS I and COS II on the content of TG. Note: COS I and COS II groups with high (3.0  105 lg L1), middle
(1.0  105 lg L1) and low (3.0  104 lg L1) concentrations, which also can be called IH, IM, IL and IIH, IIM, IIL for short
respectively. ###P< 0.001, compared with the control group, *P< 0.05, **P< 0.01, ***P< 0.001, compared with the model group.
The effect of chitooligosaccharides 297acids, oleic acid can be selected for the establishment of a lipid
accumulation model in hepatocytes, which relates to the
pathophysiological process of NAFLD (Torres et al., 2012;
Chen et al., 2015). The establishment of a hepatocyte lipid
accumulation model can be achieved through induction by
1 mmol L1 oleic acid for 24 h in HepG2 cells. After induction
by oleic acid (0.1–2 mmol L1) in a series of gradient concen-
trations in HepG2 cells, the level of intracellular lipid accumu-
lation is positively correlated with oleic acid concentration.
For this study, we chose oleic acid as the 24 h continuous
inducer for the establishment of lipid accumulating model,
which can effectively simulate the pathological process of
NAFLD, and we evaluated the roles of COS I and COS II
in eliminating lipid accumulation in hepatocytes by detecting
the conventional indexes of NAFLD such as the content of
TG and lipid droplets in hepatocytes, simultaneously. The
results show that the inhibition of TG accumulation by COS
I and COS II in the high-dose groups is the most remarkable,
with significant dose-dependent responses. Consequently, COS
I and COS II present a potential medicinal value in the preven-
tion and treatment of fatty liver. Nevertheless, the molecular
mechanisms of inhibiting lipid accumulation in response to
COS I and COS II have not been confirmed and will require
further exploration in the future.
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